Protara Therapeutics (TARA) Equity Average (2014 - 2026)

Protara Therapeutics' Equity Average history runs 13 years deep, the most recent figure standing at $188.8 million for Q1 2026.

• In Q1 2026, Equity Average rose 15.97% year-over-year to $188.8 million; the TTM figure through Mar 2026 stood at $188.8 million (up 15.97% YoY), while the FY2025 annual figure was $181.8 million, up 54.4% from the prior year.
• Equity Average was $188.8 million for Q1 2026 at Protara Therapeutics, up from $164.4 million in the prior quarter.
• In the past five years, Equity Average ranged from a high of $188.8 million in Q1 2026 to a low of $63.4 million in Q1 2024.
• Historically, Equity Average has averaged $121.6 million across 5 years, with a median of $124.5 million in 2024.
• The sharpest annual moves came in 2023 and 2025: Equity Average tumbled 43.02% in 2023, then surged 156.94% in 2025.
• A 5-year view of Equity Average shows it stood at $120.6 million in 2022, then slumped by 39.78% to $72.6 million in 2023, then surged by 71.35% to $124.5 million in 2024, then soared by 32.05% to $164.4 million in 2025, then rose by 14.88% to $188.8 million in 2026.
• The last three Equity Average figures came in at $188.8 million (Q1 2026), $164.4 million (Q4 2025), and $138.4 million (Q3 2025), per Business Quant data.